MIRA

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.26
Percentage change 20.31	%

Peers: CRON TLRY TVRD CGC ACB IIPR VFF MNMD

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.50	Insider Own	25.79%	Shs Outstand	16.81M	Perf Week	33.91%
Market Cap	26.78M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	0.00%	Shs Float	12.90M	Perf Month	27.27%
Enterprise Value	25.57M	PEG	-	EPS next Q	-0.13	Inst Own	5.47%	Short Float	1.81%	Perf Quarter	82.55%
Income	-7.92M	P/S	-	EPS this Y	26.67%	Inst Trans	-13.95%	Short Ratio	0.12	Perf Half Y	15.79%
Sales	0.00M	P/B	20.01	EPS next Y	15.58%	ROA	-304.03%	Short Interest	0.23M	Perf YTD	35.09%
Book/sh	0.08	P/C	22.13	EPS next 5Y	-	ROE	-355.82%	52W High	5.01 -69.26%	Perf Year	175.29%
Cash/sh	0.07	P/FCF	-	EPS past 3/5Y	-51.03% -224.25%	ROIC	-611.87%	52W Low	0.58 165.47%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.62% 9.32%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	37.57%	Oper. Margin	-	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.86	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	69.69	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.86	EPS Q/Q	-22.94%	SMA20	25.00%	Beta	1.73	Target Price	17.75
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	22.13%	Rel Volume	5.95	Prev Close	1.28
Employees	5	LT Debt/Eq	0.00	Earnings	May 28	SMA200	28.15%	Avg Volume	2.00M	Price	1.54
IPO	Aug 03, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	15.38% -	Trades		Volume	11,876,544	Change	20.31%

Jul-13-25 02:35PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-11-25 08:00AM	MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition (ACCESSWIRE) +6.67%
Jul-03-25 08:00AM	MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks (ACCESSWIRE)
Jun-30-25 08:00AM	MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition (ACCESSWIRE)
07:20AM	EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study (Benzinga)
08:00AM	Loading…
Jun-25-25 08:00AM	MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects (ACCESSWIRE)
Jun-18-25 08:30AM	MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology (ACCESSWIRE)
May-28-25 08:30AM	MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program (ACCESSWIRE) +6.35%
May-11-25 03:33PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
May-08-25 08:00AM	MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review (ACCESSWIRE) +7.76%
07:16AM	EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million (Benzinga)
May-06-25 08:00AM	MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity (ACCESSWIRE)
07:16AM	EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study (Benzinga)
Apr-25-25 11:30AM	Psychedelic: Clearmind completes clinical site initiations for AUD trial (TipRanks)
08:00AM	Loading…
Apr-23-25 08:00AM	MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation (ACCESSWIRE) +7.08%
Apr-16-25 08:00AM	MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion (ACCESSWIRE) +19.26%
07:15AM	EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study (Benzinga)
Apr-02-25 08:37AM	Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2 (TipRanks)
Apr-01-25 08:00AM	MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain (ACCESSWIRE)
Mar-25-25 09:00AM	Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit (TipRanks)
Mar-24-25 07:30AM	MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development (ACCESSWIRE)
07:16AM	EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug (Benzinga)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks) -5.60%
Mar-13-25 08:00AM	MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain (ACCESSWIRE) +25.00%
Mar-04-25 08:00AM	MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain (ACCESSWIRE)
07:45AM	EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain (Benzinga)
Dec-27-24 02:56AM	Memecoin Degens Raise Millions for Rare Cancer Research After a Fathers Plea (CoinDesk)
Dec-19-24 09:00AM	MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development (ACCESSWIRE)
08:25AM	EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment (Benzinga)
08:30AM	Loading…
Dec-10-24 08:30AM	MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End (ACCESSWIRE)
08:15AM	EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain (Benzinga)
Nov-20-24 07:44AM	MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site (ACCESSWIRE) -9.64%
Oct-29-24 10:57AM	MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials (GuruFocus.com) +10.19%
Oct-28-24 01:41PM	MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain (Benzinga) +21.71%
07:30AM	MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain (ACCESSWIRE)
Oct-27-24 05:34PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024 (Market Exclusive)
Oct-21-24 07:30AM	MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study (ACCESSWIRE)
Sep-27-24 07:30AM	MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024 (ACCESSWIRE) +8.41%
Sep-19-24 09:00AM	MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025 (News Direct)
Sep-18-24 07:00AM	MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 (ACCESSWIRE) -10.69%
Sep-11-24 07:30AM	MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA (ACCESSWIRE) +9.30%
Aug-26-24 08:00AM	MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study (ACCESSWIRE) +14.05%
Aug-19-24 07:30AM	MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End (ACCESSWIRE) -7.77%
Aug-12-24 08:30AM	Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman (GlobeNewswire)
08:00AM	MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor (ACCESSWIRE)
Aug-05-24 09:40AM	PayPal, Kellanova upgraded: Wall Street's top analyst calls (The Fly)
Jul-25-24 03:24PM	Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data (Benzinga) +28.81%
07:00AM	MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action (ACCESSWIRE)
Jul-22-24 12:56PM	Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today? (InvestorPlace) +627.35%
10:31AM	Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders (Benzinga)
08:00AM	MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance (ACCESSWIRE)
Jul-15-24 07:00AM	Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC (ACCESSWIRE) +25.59%
Jun-24-24 08:30AM	MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing (PR Newswire)
Jun-10-24 08:30AM	Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year (PR Newswire)
May-29-24 08:45AM	Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance (PR Newswire)
May-21-24 08:45AM	MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog (PR Newswire) +20.00%
May-20-24 08:00AM	Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog (PR Newswire) +29.77%
May-13-24 09:53PM	MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
Apr-02-24 08:00AM	Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission (PR Newswire)
Apr-01-24 02:53PM	MIRA Stock Earnings: Mira Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Mar-21-24 11:04AM	MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor (PR Newswire)
Mar-08-24 08:19AM	Why Is Mira Pharmaceuticals (MIRA) Stock Up 52% Today? (InvestorPlace) +65.28%
Feb-05-24 08:30AM	MIRA Pharmaceuticals Provides Corporate Update (PR Newswire) +45.99%
Dec-04-23 08:00AM	MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations (PR Newswire) -5.26%
Nov-29-23 08:00AM	MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% (PR Newswire)
Nov-21-23 10:42AM	MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time (PR Newswire) -16.13%
10:09AM	MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a (PR Newswire)
Nov-20-23 08:00AM	MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 (PR Newswire) +40.06%
Oct-26-23 07:23AM	MIRA: Developing Cannabis with Benefits and Without Side Effects (Zacks) +5.38%
Sep-18-23 08:30AM	MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot (PR Newswire) +38.80%
Sep-05-23 08:31AM	MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts (PR Newswire)
Aug-31-23 08:31AM	MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit (PR Newswire)
Aug-29-23 11:39AM	MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time (PR Newswire)
Aug-09-23 09:35AM	MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast (ACCESSWIRE)
Aug-03-23 02:40PM	MIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THC (News Direct)

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aminov Erez	Chief Executive Officer	Nov 19 '24	Sale	1.39	55,410	77,020	1,105,790	Nov 27 04:15 PM
Aminov Erez	Chief Executive Officer	Nov 20 '24	Sale	1.27	44,590	56,629	1,061,200	Nov 27 04:15 PM
Erez Aminov	Affiliate	Nov 19 '24	Proposed Sale	1.41	100,000	141,000		Nov 19 05:58 PM
Brian McNulty	affiliate	Sep 04 '24	Proposed Sale	1.80	10,000	18,000		Sep 04 08:20 PM
McNulty Brian Patrick	10% Owner	Aug 28 '24	Sale	1.96	200,000	392,000	2,540,270	Aug 30 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Mira Pharmaceuticals Inc

Upgrade your FINVIZ experience